Puma Biotechnology Debt
| PBYI Stock | USD 6.22 0.17 2.81% |
Puma Biotechnology has over 28.55 Million in debt which may indicate that it relies heavily on debt financing. Currently, Debt Equity Ratio is projected to drop slightly based on multi-year reporting trends. In the prior fiscal year, Debt Equity Ratio was reported at 0.22.As of now, The current year's Cash Flow To Debt Ratio is projected to rise to 1.54, whereas Net Debt is moving lower toward under -1.1 M. Puma Biotechnology financial leverage reflects the mix of debt and equity used to finance operations. Higher leverage can influence interest expense and earnings sensitivity without implying direction.
Asset vs Debt
Equity vs Debt
Puma Biotechnology's liquidity provides insight into near-term obligations and operating flexibility. Cash, liquid assets, liabilities, and equity help describe leverage and capital structure for the Company.
Please review Reconciled Depreciation and Interest Income.
For most issuers, marketable securities, inventories, and receivables are common sources of liquidity. For Puma Biotechnology, the alignment of current assets and liabilities helps support ongoing obligations.
As of now, Liabilities And Stockholders Equity is anticipated to decline to approximately 172.6 M. In addition to that, Total Current Liabilities is anticipated to decline to approximately 61.5 MReview Puma Biotechnology Financial Statements to add fundamentals context for Puma Biotechnology. This supports balance sheet and income statement context.Puma Biotechnology Debt to Cash Allocation
The debt-to-cash mix for Puma Biotechnology helps explain how management balances flexibility and funding cost through a business cycle.
Puma Biotechnology currently holds 28.55 M in liabilities with Debt to Equity (D/E) ratio of 5.19, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Puma Biotechnology has a current ratio of 2.0, which is within standard range for the sector. Note, when we think about Puma Biotechnology's use of debt, we should always consider it together with its cash and equity.Puma Biotechnology Total Assets Over Time
Puma Biotechnology Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Puma Biotechnology uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Puma Biotechnology Debt Ratio | 13.0 |
Puma Biotechnology Corporate Bonds Issued
Bond maturity for Puma Biotechnology is a core risk dimension. Longer duration can offer higher yield, but price sensitivity and credit uncertainty also increase.
Puma Net Debt
Net Debt | -1.14 Million |
What Is Puma Biotechnology Financial Leverage?
Capital structure planning starts with assessing how much external capital Puma Biotechnology needs to raise. Market conditions influence the terms at which Puma Biotechnology can issue bonds. Puma Biotechnology currently has 5 outstanding corporate bond issues in this view. We evaluate Puma Biotechnology through the lens of long-term portfolio construction and diversification efficiency.
Methodology
Unless otherwise specified, financial data for Puma Biotechnology is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Puma (USA Stocks:PBYI) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions.
Assumptions
Our reporting uses public filings and market reference sources and institutional disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Normalization procedures may introduce minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Puma Biotechnology is covered by 1 analyst. Representative analyst firms may include Bernstein Research, Deutsche Bank, Morgan Stanley, BMO Capital Markets, Guggenheim Securities, among others. Updates may occur throughout the day.
Currently Active Assets on Macroaxis
More Resources for Puma Stock Analysis
A structured review of Puma Biotechnology often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Puma Biotechnology Stock. Outlined below are key reports that provide context for Puma Biotechnology Stock:Review Puma Biotechnology Financial Statements to add fundamentals context for Puma Biotechnology. This supports balance sheet and income statement context. For information on how to trade Puma Stock refer to our How to Trade Puma Stock guide.Analysis related to Puma Biotechnology should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Quarterly Earnings Growth -0.34 | Earnings Share 0.61 | Revenue Per Share | Quarterly Revenue Growth 0.277 | Return On Assets |
The market value of Puma Biotechnology is measured differently than book value, which reflects Puma accounting equity. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Market price can move with sentiment, cycles, and liquidity conditions, so it may drift away from fundamentals. Valuation methods compare these perspectives to frame context.
Note that Puma Biotechnology's intrinsic value and market price are different measures derived from different inputs. Analysis often considers earnings, revenue quality, fundamentals, technical signals, competition, and analyst coverage. By contrast, market price reflects the level where buyers and sellers transact.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.